Novo Nordisk leads with a comprehensive GLP-1 portfolio including Ozempic, Rybelsus, and Wegovy, offering strong coverage across diabetes, obesity, and cardiovascular risk management
The physiology of glucagon-like peptide 1
**[Tirzepatide](/products/tirzepatide-001)** Dual-agonist peptide injection with up to 22.5% weight loss
Most high-quality research shows clear differences in average weight loss: Tirzepatide (Zepbound) In large clinical trials (SURMOUNT-1), tirzepatide produced 15% to 22.5% total body weight loss , depending on the dose4
Between 2021 and 2023, the global peptide therapeutics market grew from USD 37.5 billion to USD 43.1 billion, reflecting a robust CAGR during this period
Janet Woodcock, a retired FDA veteran and former principal deputy commissioner